

Axel Schlitt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4289945/publications.pdf>

Version: 2024-02-01

44
papers

1,707
citations

361388

20
h-index

276858

41
g-index

44
all docs

44
docs citations

44
times ranked

2750
citing authors

#	ARTICLE	IF	CITATIONS
1	CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF- $\hat{\pm}$ levels. <i>Thrombosis and Haemostasis</i> , 2004, 92, 419-424.	3.4	276
2	Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. <i>European Heart Journal</i> , 2017, 38, 2671-2679.	2.2	243
3	Monocyte heterogeneity in obesity and subclinical atherosclerosis. <i>European Heart Journal</i> , 2010, 31, 369-376.	2.2	172
4	High Plasma Phospholipid Transfer Protein Levels as a Risk Factor for Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1857-1862.	2.4	120
5	Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. <i>Nutrition and Metabolism</i> , 2006, 3, 5.	3.0	108
6	Cardiotoxicity and Oncological Treatments. <i>Deutsches A&#x0308;rzteblatt International</i> , 2014, 111, 161-8.	0.9	73
7	CHADS 2 , CHA 2 DS 2 -VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , 2014, 133, 560-566.	1.7	58
8	Monocyte-derived dendritic cells of patients with coronary artery disease show an increased expression of costimulatory molecules CD40, CD80 and CD86 in vitro. <i>Coronary Artery Disease</i> , 2007, 18, 523-531.	0.7	53
9	Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA). <i>Thrombosis Research</i> , 2003, 109, 131-135.	1.7	49
10	Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2005, 1733, 187-191.	2.4	49
11	PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene Study. <i>Journal of Lipid Research</i> , 2009, 50, 723-729.	4.2	35
12	C-reactive protein levels and genetic variants of CRP as prognostic markers for combined cardiovascular endpoint (cardiovascular death, death from stroke, myocardial infarction, and Tj ETQq0 0 0 rgBT /Öerlock 10̈If 50 297		
13	Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease. <i>Atherosclerosis</i> , 2017, 266, 234-239.	0.8	31
14	Performance of Bleeding Risk-Prediction Scores in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 113, 1995-2001.	1.6	26
15	Periodontal conditions and incidence of new cardiovascular events among patients with coronary vascular disease. <i>Journal of Clinical Periodontology</i> , 2016, 43, 918-925.	4.9	26
16	Prognostic value of lipoproteins and their relation to inflammatory markers among patients with coronary artery disease. <i>International Journal of Cardiology</i> , 2005, 102, 477-485.	1.7	25
17	Feasibility and safety of rehabilitation after venous thromboembolism. <i>Vascular Health and Risk Management</i> , 2015, 11, 397.	2.3	25
18	Serum sphingomyelin levels are related to the clearance of postprandial remnant-like particles. <i>Journal of Lipid Research</i> , 2005, 46, 196-200.	4.2	24

#	ARTICLE	IF	CITATIONS
19	Subgroups of monocytes predict cardiovascular events in patients with coronary heart disease. The PHAMOS trial (Prospective Halle Monocytes Study). <i>Hellenic Journal of Cardiology</i> , 2019, 60, 311-321.	1.0	24
20	Prognosis of patients with pulmonary embolism after rehabilitation. <i>Vascular Health and Risk Management</i> , 2018, Volume 14, 183-187.	2.3	23
21	Cardiac Rehabilitation in German Speaking Countries of Europe – Evidence-Based Guidelines from Germany, Austria and Switzerland LLKardReha-DACH – Part 1. <i>Journal of Clinical Medicine</i> , 2021, 10, 2192.	2.4	23
22	The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E864-70.	1.7	19
23	Herpesvirus DNA (Epstein-Barr virus, herpes simplex virus, cytomegalovirus) in circulating monocytes of patients with coronary artery disease. <i>Acta Cardiologica</i> , 2005, 60, 605-610.	0.9	18
24	Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model. <i>Thrombosis and Haemostasis</i> , 2003, 90, 245-251.	3.4	17
25	Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: The AFCAS study. <i>International Journal of Cardiology</i> , 2015, 183, 105-110.	1.7	17
26	Periodontal pathogens and their role in cardiovascular outcome. <i>Journal of Clinical Periodontology</i> , 2020, 47, 173-181.	4.9	16
27	Impact of anaemia on clinical outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. <i>BMJ Open</i> , 2014, 4, e004700.	1.9	15
28	Argatroban and bivalirudin compared to unfractionated heparin in preventing thrombus formation on mechanical heart valves. <i>Thrombosis and Haemostasis</i> , 2009, 101, 1163-1169.	3.4	13
29	Rehabilitation in Patients With Coronary Heart Disease. <i>Deutsches Arzteblatt International</i> , 2015, 112, 527-34.	0.9	13
30	In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus. <i>Coronary Artery Disease</i> , 2008, 19, 279-284.	0.7	12
31	Phospholipid Transfer Protein in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2007, 27, 138-143.	3.1	11
32	Comparison of fondaparinux, low molecular-weight heparin and unfractionated heparin in preventing thrombus formation on mechanical heart valves: results of an in-vitro study. <i>Journal of Heart Valve Disease</i> , 2006, 15, 809-14.	0.5	11
33	Bivalirudin use during percutaneous coronary intervention in patients on chronic warfarin therapy. <i>Thrombosis Research</i> , 2014, 133, 695-696.	1.7	8
34	Renal Impairment and Prognosis of Patients with Atrial Fibrillation Undergoing Coronary Intervention - The AFCAS Trial. <i>PLoS ONE</i> , 2015, 10, e0128492.	2.5	8
35	ANRIL polymorphisms (rs1333049 and rs3217992) in relation to plasma CRP levels among in-patients with CHD. <i>Cytokine</i> , 2020, 127, 154932.	3.2	8
36	Value of DAPT score to predict adverse outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: A post-hoc analysis from the AFCAS registry. <i>International Journal of Cardiology</i> , 2018, 253, 35-39.	1.7	7

#	ARTICLE	IF	CITATIONS
37	The interleukin 6 c.-174 CC genotype is a predictor for new cardiovascular events in patients with coronary heart disease within three years follow-up. <i>Cytokine</i> , 2016, 83, 136-138.	3.2	6
38	Serum Phospholipid Transfer Protein Activity After a High Fat Meal in Patients with Insulin-Treated Type 2 Diabetes. <i>Lipids</i> , 2010, 45, 129-135.	1.7	3
39	Interactive patient education via an audience response system in cardiac rehabilitation. <i>SAGE Open Medicine</i> , 2020, 8, 205031212094211.	1.8	3
40	Letter to the Editor regarding Dounousi E <i>et al</i> . Intact <i>FGF</i> ²³ and <i>Klotho</i> during acute inflammation/sepsis in <i>CKD</i> patients. <i>European Journal of Clinical Investigation</i> , 2017, 47, 468-469.	3.4	2
41	Outcome of octogenarians with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. <i>Clinical Cardiology</i> , 2017, 40, 1264-1270.	1.8	2
42	Comparison between bicycle ergometric interval and continuous training in patients early after coronary artery bypass grafting: A prospective, randomized study. <i>SAGE Open Medicine</i> , 2021, 9, 205031212110382.	1.8	2
43	Data on IL-6 c.-174 G>C genotype and allele frequencies in patients with coronary heart disease in dependence of cardiovascular outcome. <i>Data in Brief</i> , 2016, 8, 1295-1299.	1.0	1
44	Polymorphism of CD14 Gene Is Associated with Adverse Outcome among Patients Suffering from Cardiovascular Disease. <i>Mediators of Inflammation</i> , 2021, 2021, 1-10.	3.0	1